ArticleLasers in medical science2026
Effects of Terminalia fagifolia mart. extract combined with photobiomodulation on diabetic foot ulcers: protocol for a randomized single-blind clinical trial.
Article in Lasers in medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diabetic wounds are characterized by persistent inflammation, prolonged healing time, and an increased risk of amputation. The use of natural compounds combined with established therapies can increase the effectiveness of treatments for these lesions. In this context, natural products have stood out as therapeutic adjuvants due to their anti-inflammatory, antioxidant, antimicrobial, and regenerative properties. Terminalia fagifolia Mart., a medicinal species native to the Brazilian Cerrado, has a rich phytochemical composition; however, its clinical potential in wound healing has not yet been investigated. This is the first clinical trial to investigate the potential synergistic effects of Terminalia fagifolia Mart. extract, alone or in combination with photobiomodulation, on the healing of non-infected diabetic foot ulcers. A total of 102 participants with type 2 diabetes and lower limb ulcers will be randomly allocated into three groups: G1 (Terminalia fagifolia Mart. + wound occlusion), G2 (GaAs 904, 10 J/cm² + Terminalia fagifolia Mart. + wound occlusion), and a control group using Endophoton KLD (GaAs 904) at a dose of 10 J/cm² + conventional dressing. One hundred and two volunteers will be recruited and treated on two non-consecutive days per week for 10 weeks, totaling 20 sessions. The primary outcome variable will be the rate of ulcer size reduction over the 10-week period. This study is expected to provide preliminary evidence regarding the safety, feasibility, and potential efficacy of the synergistic use of T. fagifolia Mart. extract combined with photobiomodulation in the treatment of diabetic foot ulcers.Clinical trial registration This study was registered at Brazilian Clinical Trials Registry (ReBEC) on December 27, 2023 (RBR-25ng5pt || https://ensaiosclinicos.gov.br/rg/RBR-25ng5pt ).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.